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Pleural eﬀusions can present in 40% of patients with pneumonia. Presence of an eﬀusion can complicate the diagnosis as well as
the management of infection in lungs and pleural space. There has been an increase in the morbidity and mortality associated
with parapneumonic eﬀusions and empyema. This calls for employment of advanced treatment modalities and development of
a standardized protocol to manage pleural sepsis early. There has been an increased understanding about the indications and
appropriate usage of procedural options at clinicians’ disposal.
1.Introduction
Any eﬀusion that occurs secondary to an infectious process
in the lung parenchyma such as pneumonia or lung abscess
is deﬁned as a parapneumonic eﬀusion. A complicated
parapneumonic eﬀusion requires an invasive procedure for
resolution and usually a bacterial organism can be cultured
from the pleural ﬂuid [1]. When a parapneumonic eﬀusion
progresses to become frank pus, it is labeled as empyema.
Parapneumonic eﬀusion and empyema are both important
medicalconditionsassociatedwithsigniﬁcantmorbidityand
mortality.
Infection of the pleural space aﬀects approximately
60,000 individuals in the USA annually and has approxi-
mately 15% mortality [2]. About 40% of all patients diag-
nosed with pneumonia have an associated pleural eﬀusion,
out of which only a few require active intervention for
resolution [1, 3, 4]. Recent epidemiologic studies have
indicated that the incidence of empyema has been increasing
in the last two decades [5, 6].
In view of the increasing incidence and considerable
mortality and morbidity associated with pleural infections,
there is a need to utilize modern principles of empyema
management that will promote early diagnosis and prompt
pleural drainage. It has been observed that any delay in
initiating eﬀective drainage can result in prolonged hospital
stay, requirement of an invasive procedure for drainage,
and further increase in mortality and morbidity [1, 7–9]
(Table 1).
2.Pathophysiology ofa
Parapneumonic Effusion
Any inﬂammation due to an infectious process in the lung
parenchyma leads to disturbance in the delicate balance
between formation of pleural ﬂuid and its clearanceresulting
in accumulation of ﬂuid in the pleural space. This pleural
ﬂuid initially can be sterile but if left untreated can progress
to become an empyema. This progression occurs in three
stages (Table 2)[ 10].
At the very beginning, inﬂammation due to pneumonia
in the lung parenchyma increases vascular as well as visceral
pleural membrane permeability by molecules like vascular
endothelial growth factor (VEGF) and there is outpouring
of inﬂammatory ﬂuid in the pleural space [11]. This is
known as the exudative phase. At this stage, the pleural
ﬂuid is nonviscous, free-ﬂowing, and readily drained by
thoracentesis or chest tube. During this stage, pleural ﬂuid
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Table 1: Pleural infections staging and recommended drainage [7].
Category Pleural space anatomy Pleural ﬂuid chemistry Risk of poor outcome Drainage
1 Minimal free-ﬂowing eﬀusion (<10mm on
lateral decubitus) and Gram stain and culture results
unknown Very low No
2 Small to moderate free-ﬂowing eﬀusion
(≥10mm and less than one half hemithorax) and Negative Gram stain and culture Low No
3
Large, free-ﬂowing eﬀusion (≥ one half
hemithorax), loculated eﬀusion, or eﬀusion
with thickened parietal pleura
or Positive Gram stain and/or culture Moderate Yes
4 Empyema pus High Yes
Table 2: Diﬀerent stages in the evolution of an infected pleural
eﬀusion with associated pathological changes and pleural ﬂuid
ﬁndings.
Phase Pathology Pleural ﬂuid ﬁndings
Exudative
Increased
permeability of
vascular and visceral
pleural membranes
VEGF
Nonviscous
Free ﬂowing
Readily drained
Pleural ﬂuid Cx negative
Fibrinopurulent
Fibrin deposition on
visceral pleura
Locules formation
IL-8, TNF-α
pH > 7.20
Glucose within normal
ranges
LDH < 3 times ULN
Viscous
More viscous
Pleural ﬂuid cx positive
Typical “complicated”
eﬀusion
Organizing
Fibroblast entry
Pleural peel
TGF-β
Thick pus
Very viscous
pH < 7.20
Glucose < 40
LDH > 3 times ULN
LDH: lactate dehydrogenase.
ULN: upper limits of normal.
VEGF: vascular endothelial growth factor.
IL-8: interleukin 8.
TNF-α: tumor necrosis factor-alpha.
TGF-β: transforming growth factor-beta.
level is within the normal range and lactate dehydrogenase
remains <3 times the upper limit of normal [12].
If the inﬂammation proceeds unabated, it leads to
purulent and increasingly viscous pleural ﬂuid, which is
now rich in inﬂammatory cytokines like IL-1 and TNF-
α. IL-1 induces mesothelial cells to release transforming
growth factor (TGF-β) which is one of the most potent
ﬁbrogenic agents ever discovered [13]. This second stage
called ﬁbrinopurulent phase is characterized by positive
microbial cultures and the eﬀusion now is referred to as
“complicated” (Figure 1). Patients with complicated parap-
neumonic eﬀusions have higher pleural ﬂuid levels of TNF-
α, which is a marker of the degree of inﬂammation, than
do patients with uncomplicated parapneumonic eﬀusions
[14]. Pleural infection during this stage may respond to
antibiotics and chest tube drainage but often requires
invasive intervention. This is because of the continuing
inﬂammation that there is a deposition of ﬁbrin over the
visceral pleura which in turn results in the formation of
adhesions that impede lung re-expansion during attempts
at ﬂuid drainage. When the pleura is inﬂamed, the amount
of ﬁbrin that is laid down is the result of the balance
between ﬁbrinogenesis and ﬁbrinolysis. Fibrogenesis occurs
when the factors that favor ﬁbrogenesis such as TNF-α,
TGF-β, and plasminogen activation inhibitor-1 (PAI-1) are
dominant. Fibrinolysis occurs when more ﬁbrin is being
broken down than is being created [15]. If a ﬁbrinopurulent
eﬀusion remains undrained, ﬁbroblasts eventually deposit
ﬁbrotic tissue that encases the lung in inelastic peels [16–
18]. At this organizing phase, thick pleural peel restricts
chest mechanics and often requires surgical decortications to
address restrictive impairment.
3.Bacteriology
The bacteria isolated from infected pleural eﬀusion vary
signiﬁcantly between community- and hospital-acquired
infections. Maskell et al. conducted a large prospective MIST
1 trial (Multicenter Intrapleural Sepsis Trial 1) in 2005 [19].
In their study, 430 subjects were enrolled from 52 centres in
the United Kingdom. Positive pleural cultures were found
in 232 (54%) of the subjects. The most common pathogen
isolated was Streptococcus milleri group (29%), followed
by staphylococci (21%) and Streptococcus pneumonia (16%).
Only 15% of eﬀusions had anaerobes. Less common organ-
isms responsible for community-acquired infection include
other streptococci, enterobacteria, Haemophilus inﬂuenzae,
Pseudomonas spp., tuberculosis, and Nocardia. In an earlier
study [20], it was reported that nosocomial pleural infec-
tions were most commonly caused by methicillin-resistant
Staphylococcus aureus (27%), other staphylococci (22%) and
enterobacteria (20%). Similar results were seen in a recent
study of empyema in the intensive care unit setting by Tu
et al. [21]. They found that Klebsiella pneumoniae was the
most isolated microbe and also there was a high prevalence
of polymicrobial infection. Even though the MIST 1 trial
showed a low incidence of anaerobic organisms causing
pleural infections, it is well known that they are diﬃcult
to isolate by culture of ﬂuid and/or blood. Previous studies
have shown that anaerobic bacteria were cultured in 36Pulmonary Medicine 3
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Figure 1: Aseriesof CTimages done inpatient with parapneumonic eﬀusions.(a)CTimage showingafreeﬂowing pleuraleﬀusion (r)with
a meniscus formation (arrow). There is also some ﬂuid in the ﬁssure on the left side (L). (b) A loculated pleural eﬀusion with loculations
seen in the pleural space (arrows). (c) A chronic pleural eﬀusion showing marked pleural thickening (arrows).
to 76 percent of human empyemas [22, 23]w i t hp r e d o m -
inant organisms isolated being Fusobacterium nucleatum,
Prevotella sp, Peptostreptococcus, and the Bacteroides fragilis
group although B. fragilis is relatively rare [22, 24, 25].
4. Therapeutic Approaches to Manage
PleuralInfections
There are very few randomized trials regarding management
of pleural infections. This limits the evidence base to small
observational reports and expert opinions leading to con-
siderable variation in the treatment of individual patients.
Depending on institutional expertise, the management of
pleural infections can range from noninvasive treatment
such as observation and antibiotic therapy to aggressive as
well as invasive procedures like therapeutic aspiration, tube
thoracostomy and intrapleural ﬁbrinolytics, thoracoscopy,
thoracotomy, or open drainage [12].
In recent times, application of these treatment modalities
has been greatly aided by advanced imaging studies. With
various imaging as well as treatment options at our disposal,
there is a need for development of a multidisciplinary
approach that can coordinate pulmonary, thoracic surgery,
and interventional radiology expertise.
4.1. Antibiotics. Almost all patients with parapneumonic
eﬀusion will need antibiotic coverage. This coverage can be
to treat the pneumonia or empirical coverage for a suspected
pleural sepsis [1]. Even if the pleural ﬂuid cultures are
negative and there is a strong suspicion of pleural infection,
clinician should initiate an empiric anaerobic coverage as
an anaerobic infection will not grow well on culture media.
According to the bacteriology listed for a community-
acquired infection before the ﬁrst choice will include intra-
venous amoxicillin with clavulanic acid or a combination
of a second-generation cephalosporin (e.g., cefuroxime) and
metronidazole or clindamycin if patient is penicillin allergic4 Pulmonary Medicine
[26] patients with nosocomial empyema need adequate
Gram-negative coverage, as Gram-negative infections are
more common in nosocomial empyemas. Coverage should
include at least a carbapenem or an antipseudomonal
penicillin (e.g., piperacillin/tazobactam), or third- or fourth-
generation cephalosporins (e.g., ceftazidime, cefepime) with
metronidazole. If there is a suspicion for MRSA, coinfection
vancomycinorlinezolidcanbeadded.Thesingleexceptionis
that aminoglycosides may be inactivated at low pleural ﬂuid
pH [27].
4.2. Serial Thoracentesis. Therapeutic thoracentesis has been
used for the treatment of parapneumonic eﬀusions for
almost two centuries [28]. In recent times, treating empyema
or complicated parapneumonic eﬀusions with serial thera-
peutic pleural aspirations has been largely abandoned. There
have been no controlled studies comparing therapeutic
thoracentesis with small-tube thoracostomy in the treatment
of patients with complicated nonloculated parapneumonic
eﬀusions. Most of the recommendations are from some
centers [29, 30] who advocate that patients should have
daily therapeutic thoracentesis with or without pleural
lavage in case of recurrence of infected eﬀusions after
initial thoracentesis to allow the pleural ﬂuid to freely ﬂow
without any formation of locules until antibiotics resolve
the infection. This approach may require an average of eight
thoracentesis in >2 to 4 weeks. This was shown in a recent
study done by Simmers et al. [31] in which they were able
to successfully treat 24 of 29 patients with parapneumonic
eﬀusions by means of alternate-day ultrasound-guided pleu-
ral aspirations. This approach required that the patients
undergo an average of 7.7±3.5 thoracentesis with an average
hospitalization of 31 days.
4.3. Chest Tube Drainage. Current indications for chest tube
drainage are the aspiration of frankly purulent pleural ﬂuid,
theidentiﬁcationoforganismsonpleuralﬂuidGramstainor
culture,orapleuralﬂuidpH < 7.2intheclinicalsettingofa
pneumonicillness[32].Asanexceptioninaverylargesimple
parapneumonic eﬀusion, chest tube drainage may be done
for symptomatic relief. According to old literature, chest
tube drainage is most commonly achieved by a standard
(24–28 french) intercostal chest drain, that is, positioned in
the dependent part of a free-ﬂowing pleural eﬀusion (most
often the posterior costophrenic recess). Using an imaging
modality like ultrasound for inserting chest tube is advised
as thickened parietal pleura, adhesions, or loculations often
complicate insertion. Complete re-expansion of the lung,
as demonstrated by repeat imaging, resolution of clinical
and laboratory signs of infection, and avoidance of surgical
drainage, deﬁnes successful drainage.
Till recent times, the common thinking was that smaller
bore chest drains are likely to fail in the presence of pus with
a high viscosity. However, some prospective studies [33–35]
have found that 8- to 12-french pigtail catheters or 10- to 14-
french catheters inserted with the Seldinger technique under
US or CT guidance (Figure 2) were at least as eﬀective as
larger catheters inserted without imaging. Occlusion of the
smaller drains can be avoided by the use of suction (20cm
H2O) and regular ﬂushes (e.g., 30mL normal saline every
6 hours). If the patient has not demonstrated signiﬁcant
improvement within 24h of initiating tube thoracostomy,
either the pleural drainage is unsatisfactory or the patient
is receiving the wrong antibiotics. Unsatisfactory pleural
drainage can be due to the tube being in the wrong location,
loculation of the pleural ﬂuid, or a ﬁbrinous coating of the
visceral pleura, which prevents the underlying lung from
expanding. If drainage is inadequate, ultrasonography or
a CT scan should be obtained to delineate which of the
above factors is responsible. Data is still lacking to deﬁne
the right time to remove the chest drain and thus general
recommendations are to remove the drain when the daily
output falls to less than 150cc for 2 consecutive days, in the
setting of clinical and radiographic improvement.
The evidence base developing for small bore drains
estimates a failure rate of 19% with their use in draining
empyema [36]. A very recent study [35] of 71 complicated
parapneumonic eﬀusions and 70 empyemas drained with
ultrasonographicallyguidedsmallcathetersshowedasuccess
rate of 80% (48/60) when the initial ultrasonography did
not reveal signiﬁcant loculations. In those patients with a
complex septated pattern on ultrasonography, the success
rate was still 51% (41/81). Authors concluded that the
threshold for using ﬁbrinolytics and large-bore catheters
should be low in empyema.
Long-term indwelling catheters (Figure 3) are being
increasingly used to drain malignant pleural eﬀusions.
Development of infection in the pleural space has been
cited as a complication of this product. An article was
published in 2008 [37] with two reports of use of indwelling
catheters to treat pleural infection. The ﬁrst case had a
persistent bronchopleural ﬁstula and the second case had
esophageal rupture due to necrotizing TB lymphadenitis
resulting in development of empyema in both cases. These
cases suggested that small-bore indwelling catheters can have
as successful outcomes as open drainage procedures and in
addition provide patients with better quality of life during
sustained pleural drainage. The current understanding is
that during the early phase of pleural infection, short-term
ﬁne-bore pigtail catheter drainage can be useful, while for
chronicpleuralinfection,long-termdrainagecanbeeﬀective
without the problems of catheter blockage or tract infection.
This approach needs validation with larger patient samples
and randomized trials.
4.4.IntrapleuralFibrinolyticsandDNase. Drainageofpleural
ﬂuid becomes challenging when there is formation of
loculations inside the pleural cavity which resist drainage
with a single chest tube. This has generated considerable
interest in the use of intrapleural ﬁbrinolytic agents and
DNase (Table 3), which may facilitate ﬂuid drainage by
dissolving ﬁbrinous adhesions. Development of dense layers
of ﬁbrin and loculations in a complicated parapneumonic
eﬀusions and empyemas are as a result of the procoag-
ulant state within the pleural space as discussed in the
pathophysiology of pleural infections. It, therefore, seemsPulmonary Medicine 5
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Figure 2: CT images after chest tube drainage. (a) Image shows placement of pigtail catheter (arrow) in the posterior recess conﬁrmed with
CT. (b) Placement of small-bore pigtail catheter (arrowheads) in the small loculated eﬀusion with the help of CT guidance.
Figure 3:Apictorialrepresentationofachronicindwellingcatheter
(Aspira) which is tunneled beneath the skin to enter the pleural
cavity at a distant site. This assembly prevents introduction of
infection in the pleural cavity and can provide long term drainage
of infected pleural eﬀusion.
highly plausible that intrapleural ﬁbrinolytics given early
in the ﬁbrinopurulent phase should prevent loculations
and promote pleural drainage. Small studies [38–41]h a v e
reported the beneﬁcial eﬀects of therapy with streptokinase,
urokinase, and rtPA for avoiding surgery and improving
Table 3: Various intrapleural ﬁbrinolytics (Adapted from Colice et
al. [7]).
Fibrinolytic Dose Instillation Duration
Streptokinase 250,000IU 100–200cc NS QD for up to 7 days
Urokinase 10,000IU 100 ccNS QD for up to 3 days
t-PA 10–25mg 100 ccNS BID for up to 5 days
t-PA: tissue plasminogen activator.
IU: international units.
NS: normal saline.
QD: every day.
BID: twice a day.
the radiographic appearance of loculated eﬀusions. Based
on these early reports of eﬃcacy from smaller studies, the
BTS [26, 42] and the ACCP [7]( Table 1) guidelines have
recommended ﬁbrinolytic drugs as possible management
options.
Till date, the largest randomized control trial of ﬁbri-
nolytic therapy is the Multicenter Intrapleural Sepsis Trial
(MIST1) done by Maskell et al. [19]. Study centers in
this trial placed small-bore chest tubes (median size, 12F)
without image guidance in 427 patients with complicated
parapneumonic eﬀusions (pleural ﬂuid pH < 7.20, with
signs of infection, or positive ﬁndings from a pleural ﬂuid
Gram stain or culture) or frank empyema and instilled
streptokinase or placebo. The trial observed no beneﬁts from
streptokinase administration in terms of survival, decreased
hospital stay, or need for surgery. However, there was a
criticism about the methodology and implementation of this
trial [43–45]. Patients did not undergo CT scanning or US
imaging to identify locules or place chest tubes, and correct
tube positioning was not conﬁrmed after placement. There
were concerns about the generalization of ﬁndings as no
standardized protocols were used across the 52 centers to
direct antibiotic or other treatments or to select patients who6 Pulmonary Medicine
Figure 4: Thoracoscopic views of a complicated parapneumonic eﬀusion. Multiple pleural adhesions (black arrowheads) are seen which
prevent lungs from re-expanding. There are also seen inﬂamed pleura (white arrowheads) which represent nonresolving infection.
had not responded to ﬁbrinolysis for surgery. Many of these
centerslackedon-sitesurgicalexpertiseandcontributedonly
small numbers of patients. Even the drainage techniques
were questioned as study design permitted small-bore chest
tubes but did not report on pleural drainage volumes.
Furthermore, streptokinase was mailed to study centers
after randomization, which delayed ﬁbrinolysis. Mortality
as one of the endpoints was doubted as patients with
serious concomitant illnesses that made survival beyond
three months unlikely were excluded from the study. It
was speculated that use of intrapleural streptokinase might
yield better results in improving short-term mortality in a
carefully selected patient population [43]. These deﬁciencies
do not invalidate this large randomized trial, but concerns
remain about the validity of its results with regards to
younger,moreseverelyillpatientsandindiﬀerenthealthcare
settings.
Streptokinase often loses eﬀectiveness due to immune-
mediated neutralization; therefore, studies [40, 46, 47]h a v e
been done using rtPA as the primary ﬁbrinolytic. These
studies estimate success rate of 86% with rtPA.
Similar results as in MIST1 were found in a meta-
analysis [48] done subsequently to evaluate the beneﬁt of
ﬁbrinolytic therapy in pleural sepsis. A Cochrane review [49]
that included some studies (n = 761) also failed to show a
reduction in death among patients who received ﬁbrinolytic
therapy (28 versus 33 percent). In view of conﬂicting results
in diﬀerent studies, currently there is not enough evidence
to support routine ﬁbrinolytic therapy for every patient with
parapneumonic eﬀusions.
Deoxyribose nucleoprotein content plays a major role
in increasing the viscosity of pus in the pleural space.
Intrapleural ﬁbrinolytics have negligible eﬀects on decreas-
ing the viscosity of empyema pus in contrast to agents that
depolymerize DNA, such as human recombinant deoxyri-
bonuclease. Beneﬁt of intrapleural human recombinant
DNase in the treatment of empyema following failure of
streptokinase has been reported only in case reports [50].
In a recent UK trial comparing the eﬀects of intrapleural
tPA, intrapleural ﬁbrinolytics and both combined with
placebo showed insigniﬁcant response in pleural infection
resolution with tPA or DNase alone. On the other hand,
the combination of tPA-DNase instilled in the intrapleural
space improved ﬂuid drainage and reduced the frequency of
surgical referral and the duration of the hospital stay [51].
These initial case reports and trial hint toward a potential
new therapy which can improve outcomes of semi-invasive
therapies.
4.5. Thoracoscopy. Thoracoscopy is a technique which is able
to provide a minimally invasive access to the pleural space
to suction viscous pleural ﬂuid, lyse adhesion in loculated
pleural eﬀusions, and place chest tubes in dependent regions
of pleural ﬂuid under direct visualization [12]. Loculations
can be broken down, the visible pleural space completely
drained, and an intercostal chest tube can be optimally
placed [12]. Thoracoscopy in comparison to thoracostomy
has the advantage of having less postoperative pain, lower
costs, shorter hospital stays, and better cosmetic results
[52]. Available thoracoscopic procedures include medical
thoracoscopy and video-assisted thoracoscopic surgery (V-
ATS).
Medical thoracoscopy (Figure 4) has been shown to
provide resolution of tuberculous pleural eﬀusions byPulmonary Medicine 7
Patient with a pleural 
effusion suspicious for 
infection
Diagnostic pleural tap
Pleural ﬂuid ﬁndings consistent with infection
Size of the pleural effusion
Small to medium uncomplicated effusion
Antibiotics and 
observation Serial 
thoracentesis
Resolution
No further treatment
No resolution
Imaging showing multiple loculations
Medical thoracoscopy
VATS
Open drainage
with or without 
debridement/decortication
Chronic indwelling catheters
Pleural ﬂuid ﬁndings inconsistent with infection
Look for other causes 
of pleural effusion
Chronic effusion
Large complicated eﬀusion∗
Chest tube drainage
Small bore?
Large bore?
Intrapleural ﬁbrinolytics?
Intrapleural DNase?
Intrapleural ﬁbrinolytic-DNase?
Figure 5: A schematic ﬂow chart summarizing the various treatment modalities available for managing pleural infection and various
stages where each of them may be used. Decisions regarding timing of each treatment option may vary according to institutional expertise.
∗Empyema or eﬀusions with either gram stain or culture positive, pH < 7.2, glucose < 60mg/dL, LDH < 1000.
repeated adhesionolysis since early part of 20th century in
Europe [53, 54]. Medical thoracoscopy is a cheap and quick
procedure which can easily be done in an endoscopy suit
with patient under conscious sedation and breathing spon-
taneously within 30–60 minutes [55]. Medical thoracoscopy
is performed via single chest port in contrast to VATS, and
does not require complete collapse of the lung. Limitation
of medical thoracoscopy lies in its inability to fully examine
the pleural cavity and to perform pleurectomy if needed.
Additionally, debridement done using medical thoracoscopy
is time consuming and cumbersome.
Again, there has been a lack of large randomized con-
trolled trial for establishing the role of medical thoracoscopy.
A recent case series [56] which analyzed the beneﬁt of
medical thoracoscopy for treatment of ultrasonographically
stratiﬁed multiloculated pleural eﬀusion showed a primary
success rate of 91%. Taking in account patients who required
additional chest tube insertion or second medical thora-
coscopy procedure, the success rates further improved to
94%. 6% of cases required conversion to open drainage. This
case series reported the use of intrapleural ﬁbrinolytics as an
adjunctive therapy after the thoracoscopy procedure in 49%
of cases. Complications occurred in 9% of patients with no
mortality observed due to the procedure itself.
VATS is a procedure which is performed by a cardio-
thoracic surgeon generally using a three-entry port and a
double-lumen endotracheal tube. Using VATS, surgeons can
also perform decortication and pleurectomy if needed. Even
though VATS in comparison to medical thoracoscopy can
provide the operator with a much larger access to the pleural8 Pulmonary Medicine
space, it may still prove out to be inadequate to treat thick
empyemas complicated by dense adhesions and multiple
loculations. Studies on VATS procedure have reported a
success rate of 60–100%. Currently, VATS is reserved for
treating complicated ﬁbrinopurulent eﬀusions, with some
surgeons using it during the organizing phase and then
converting to thoracostomy if it fails [57–60].
4.6. Open Drainage. An open drainage procedure is
employed when the minimally invasive procedures fail to
achieve acceptable resolution, deﬁned as re-expansion of
lung to the chest wall. In the early exudative or ﬁbrinopuru-
lent stages, an open drainage procedure helps to control the
pleural sepsis while the main aim in an organizing phase is to
remove the ﬁbrotic peel that encasesthe lung in order to help
it to re-expand and improve chest dynamics [12, 61, 62].
Opendrainageisachievedusingtwotypesofapproaches.
First being thoracotomy with drainage and subsequent
closure of the chest with one or more drains left in the
pleural cavity. Second approach involves creating a window
in the pleural cavity by chest wall incision and rib resection,
which provides continuous drainage of the chest cavity. This
is called thoracostomy. Through the window in the chest
wall drainage can be facilitated by inserting chest tubes.
After complete removal of the empyema, chest tubes can
be withdrawn. Thoracotomy procedure can also help in
complete or partial decortication of the pleural membranes
coated with ﬁbrous tissue which will in turn expedite evac-
uation of thick pus in the pleural cavity and let the lung re-
expand [63]. Debridement in comparison to decortication
which is a major thoracic operation is less aggressive and can
be better tolerated by patients who are markedly debilitated
[64].
In a review of 25 patients [65] who underwent either
decortication or debridement for empyema drainage, the
outcomes were studied by measuring the change of the pleu-
ral cavity size before, immediately after surgery, and on fol-
lowup. On followup imaging, the eventual size of the pleural
cavity was not diﬀerent between the two procedure groups
(P<0.937). Thus, almost similar results were achieved by
debridement alone without decortication in patients pre-
senting with empyema, despite the presence of an underlying
trapped lung.
5. Conclusions
The management principles for pleural infection have come
a long way from employing antibiotic therapy and thoracen-
tesis to the current availability of semi-invasive and invasive
procedures. The key to successful management of pleural
infection still remains to be early diagnosis and initiation
of treatment. Due to the paucity of robust clinical trials,
the treatment modality or the management approach chosen
largely depends on individual and institutional expertise.
Clinicians are encouraged to develop standardized protocols
using best practices reported in the literature, for early
identiﬁcation and management (Figure 5).
Use of advanced imaging like ultrasound and CT scans
widens the scope of diagnosing and treating eﬀusions seen
on a routine postero-anterior chest radiograph. Observation
is usually adequate for a small (<10mm) unseptated, free
ﬂowing eﬀusions. Any other eﬀusions warrant a diagnostic
thoracentesis. If the aspirated ﬂuid fulﬁlls the criteria for
being infected (pH < 7.2, glucose < 40mg/dL, culture
positive), a prompt plan for its drainage is needed. Currently,
large bore tube thoracostomy is the treatment option of
choice for patients with empyema, but data is accumulating
for treating parapneumonic eﬀusions with small-bore inter-
costal drains.
The use of ﬁbrinolytics still remains controversial. Fib-
rinolytics will have more deﬁned role for treating loculated
parapneumonic eﬀusions and empyema, particularly in
young, acutely ill patients, poor surgical candidates, and in
centreswithinadequatesurgicalfacilities.Earlythoracoscopy
is an alternative to thrombolytics. Local expertise will dictate
the choice between therapeutic thoracentesis, intrapleural
ﬁbrinolytics, and medical thoracoscopy as well as conversion
to open drainage when thoracoscopy fails till randomized
trials provide with better evidence.
References
[ 1 ]S .J .C h a p m a na n dR .J .O .D a v i e s ,“ R e c e n ta d v a n c e si n
parapneumonic eﬀusion and empyema,” Current Opinion in
Pulmonary Medicine, vol. 10, no. 4, pp. 299–304, 2004.
[2] S. A. Sahn, “Management of complicated parapneumonic ef-
fusions,” American Review of Respiratory Disease, vol. 148, no.
3, pp. 813–817, 1993.
[3] C. W. H. Davies, S. E. Kearney, F. V. Gleeson, and R. J. O.
Davies, “Predictors of outcome and long-term survival in
patients with pleural infection,” American Journal of Respira-
tory and Critical Care Medicine, vol. 160, no. 5 I, pp. 1682–
1687, 1999.
[4] A.K.Mandal,H.Thadepalli,A.K.Mandal,andU.Chettipally,
“Outcome of primary empyema thoracis: therapeutic and
microbiologic aspects,” Annals of Thoracic Surgery, vol. 66, no.
5, pp. 1782–1786, 1998.
[5] F. Farjah, R. G. Symons, B. Krishnadasan, D. E. Wood, and
D. R. Flum, “Management of pleural space infections: a
population-based analysis,”Journal of Thoracic and Cardiovas-
cular Surgery, vol. 133, no. 2, pp. 346–351, 2007.
[6] C.Finley ,J .Clift on,J .M.FitzGerald,andJ .Y ee,“Empy ema:an
increasing concern in Canada,” Canadian Respiratory Journal,
vol. 15, no. 2, pp. 85–89, 2008.
[7] G. L. Colice, A. Curtis, J. Deslauriers et al., “Medical and
surgical treatment of parapneumonic eﬀusions: an evidence-
based guideline,” Chest, vol. 118, no. 4, pp. 1158–1171, 2000.
[ 8 ]J .E .H e ﬀner, J. McDonald, C. Barbieri, and J. Klein, “Man-
agement of parapneumonic eﬀusions: an analysis of physician
practice patterns,” Archives of Surgery, vol. 130, no. 4, pp. 433–
438, 1995.
[ 9 ] M .W .A .C h u ,L .R .S .D e w a r ,J .J .B u r g e s s ,a n dE .G .F .B u s s e ,
“Empyema thoracis: lack of awareness results in a prolonged
clinical course,” Canadian Journal of Surgery,v o l .4 4 ,n o .4 ,p p .
284–288, 2001.
[ 1 0 ] N .C .A n d r e w s ,E .F .P a r k e r ,R .R .S h a we ta l . ,“ M a n a g e m e n to f
nontruberculous empyema,” American Review of Respiratory
Disease , vol. 85, pp. 935–936, 1962.Pulmonary Medicine 9
[11] C. S. Grove and Y. C. G. Lee, “Vascular endothelial growth fac-
tor: the key mediator in pleural eﬀusion formation,” Current
Opinion in Pulmonary Medicine, vol. 8, no. 4, pp. 294–301,
2002.
[12] R. W. Light, “Parapneumonic eﬀusions and empyema,” Pro-
ceedings of the American Thoracic Society, vol. 3, no. 1, pp. 75–
80, 2006.
[13] C. L. Chung, C. H. Chen, J. R. Sheu, Y. C. Chen, and S. C.
Chang, “Proinﬂammatory cytokines, transforming growth
factor-β1, and ﬁbrinolytic enzymes in loculated and free-
ﬂowing pleural exudates,” Chest, vol. 128, no. 2, pp. 690–697,
2005.
[14] M. G. Alexandrakis, S. A. Coulocheri, D. Bouros, and G. D.
Eliopoulos, “Evaluation of ferritin, interleukin-6, interleukin-
8 and tumor necrosis factor alpha in the diﬀerentiation of
exudates and transudates in pleural eﬀusions,” Anticancer
Research, vol. 19, no. 4 C, pp. 3607–3612, 1999.
[15] S. Idell, C. Zwieb, A. Kumar, K. B. Koenig, and A. R. Johnson,
“Pathways of ﬁbrin turnover of human pleural mesothelial
cells in vitro,” American Journal of Respiratory Cell and
Molecular Biology, vol. 7, no. 4, pp. 414–426, 1992.
[16] S. Idell, W. Girard, K. B. Koenig, J. McLarty, and D. S. Fair,
“Abnormalities of pathways of ﬁbrin turnover in the human
pleural space,” American Review of Respiratory Disease, vol.
144, no. 1, pp. 187–194, 1991.
[17] C.Alem´ an,J.Alegre,J.Monasterioetal.,“Associationbetween
inﬂammatory mediators and the ﬁbrinolysis system in infec-
tious pleural eﬀusions,” Clinical Science, vol. 105, no. 5, pp.
601–607, 2003.
[18] S. A. Sasse, M. R. Jadus, and G. D. Kukes, “Pleural ﬂuid trans-
forming growth factor-β1 correlates with pleural ﬁbrosis in
experimental empyema,” American Journal of Respiratory and
Critical Care Medicine, vol. 168, no. 6 I, pp. 700–705, 2003.
[19] N. A. Maskell, C. W. H. Davies, A. J. Nunn et al., “U.K. con-
trolledtrialofintrapleuralstreptokinaseforpleuralinfection,”
New England Journal of Medicine, vol. 352, no. 9, pp. 865–874,
2005.
[20] N. A. Maskell, C. W. Davies, E. Jones, and R. J. O. Davies,
“The characteristics of 300 patients participating in the
MRC/BTS multicenter intra-pleural streptokinase vs. placebo
trial (ISRCTN-39138989),” in Proceedings of the American
Thoracic Society Meeting, Atlanta, Ga, USA, 2002.
[21] C.Y .T u,W .H.Hs u,T .C.Hsiaetal.,“Thec hangingpathog e ns
of complicated parapneumonic eﬀusions or empyemas in a
medical intensive care unit,” Intensive Care Medicine, vol. 32,
no. 4, pp. 570–576, 2006.
[22] I. Brook and E. H. Frazier, “Aerobic and anaerobic micro-
biology of empyema: a retrospective review in two military
hospitals,” Chest, vol. 103, no. 5, pp. 1502–1507, 1993.
[23] J.G.Bartlett,S.L.Gorbach,H.Thadepalli,andS.M.Finegold,
“Bacteriology of empyema,” The Lancet, vol. 1, no. 7853, pp.
338–340, 1974.
[24] R. Civen, H. Jousimies-Somer, M. Marina, L. Borenstein, H.
Shah, and S. M. Finegold, “A retrospective review of cases of
anaerobic empyema and update of bacteriology,” Clinical
Infectious Diseases, vol. 20, supplement 2, pp. S224–S229,
1995.
[25] L. Boyanova, G. Gergova, D. Iotov et al., “Anaerobic micro-
biology in 198 cases of pleural empyema: a Bulgarian study,”
Anaerobe, vol. 10, no. 5, pp. 261–267, 2004.
[26] C. W. H. Davies, F. V. Gleeson, and R. J. O. Davies, “BTS
Pleural Disease Group, a sub-group of the BTS Standards of
Care Committee: BTS guidelines for the management of
pleuralinfection,”Thorax,vol.58,supplement2,pp.ii18–ii28,
2003.
[27] P. Vaudaux and F. A. Waldvogel, “Gentamicin inactivation
in purulent exudates: role of cell lysis,” Journal of Infectious
Diseases, vol. 142, no. 4, pp. 586–593, 1980.
[28] H. I. Bowditch, “Paracentesis thoracic: an analysis of 25 cases
of pleuritic eﬀusion,” American Medical Monthly, pp. 3–45,
1853.
[29] H. K. Ryaa Storm, M. Krasnik, K. Bang, and N. Frimodt-
Moller, “Treatment of pleural empyema secondary to pneu-
monia: thoracocentesis regimen versus tube drainage,” Tho-
rax, vol. 47, no. 10, pp. 821–824, 1992.
[30] S.Sasse,T.Nguyen,L.R.Teixeira,andR.W.Light,“Theutility
of daily therapeutic thoracentesis for the treatment of early
empyema,” Chest, vol. 116, no. 6, pp. 1703–1708, 1999.
[31] T. A. Simmers, C. Jie, and B. Sie, “Minimally invasive
treatment of thoracic empyema,” Thoracic and Cardiovascular
Surgeon, vol. 47, no. 2, pp. 77–81, 1999.
[32] J. E. Heﬀner, L. K. Brown, C. Barbieri, and J. M. DeLeo,
“Pleural ﬂuid chemical analysis in parapneumonic eﬀusions:
a meta-analysis,” American Journal of Respiratory and Critical
Care Medicine, vol. 151, no. 6, pp. 1700–1708, 1995.
[33] S. Shankar, M. Gulati, M. Kang, S. Gupta, and S. Suri, “Image-
guided percutaneous drainage of thoracic empyema: can
sonography predict the outcome?” European Radiology, vol.
10, no. 3, pp. 495–499, 2000.
[34] I. Ali and H. Unruh, “Management of empyema thoracis,”
Annals of Thoracic Surgery, vol. 50, no. 3, pp. 355–359, 1990.
[35] D.G.Ashbaugh,“Empyemathoracis:factorsinﬂuencingmor-
bidity and mortality,” Chest, vol. 99, no. 5, pp. 1162–1165,
1991.
[36] A.N.Keeling,S.Leong,P.M.Logan,andM.J.Lee,“Empyema
and eﬀusion: outcome of image-guided small-bore catheter
drainage,” CardioVascular and Interventional Radiology, vol.
31, no. 1, pp. 135–141, 2008.
[37] H. E. Davies, N. M. Rahman, R. J. Parker, and R. J. O. Davies,
“Use of indwelling pleural catheters for chronic pleural
infection,” Chest, vol. 133, no. 2, pp. 546–549, 2008.
[38] A. H. Diacon, J. Theron, M. M. Schuurmans, B. W. Van De
Wal, and C. T. Bolliger, “Intrapleural streptokinase for em-
pyema and complicated parapneumonic eﬀusions,” American
Journal of Respiratory and Critical Care Medicine, vol. 170, no.
1, pp. 49–53, 2004.
[39] D. Bouros, S. Schiza, N. Tzanakis, G. Chalkiadakis, J. Drositis,
and N. Siafakas, “Intrapleural urokinase versus normal saline
in the treatment of complicated parapneumonic eﬀusions
and empyema: a randomized, double-blind study,” American
Journal of Respiratory and Critical Care Medicine, vol. 159, no.
1, pp. 37–42, 1999.
[40] D. A. Gervais, D. A. Levis, P. F. Hahn, R. N. Uppot, R. S.
Arellano, and P. R. Mueller, “Adjunctive intrapleural tissue
plasminogen activator administered via chest tubes placed
with imaging guidance: eﬀectiveness and risk for hemor-
rhage,” Radiology, vol. 246, no. 3, pp. 956–963, 2008.
[ 4 1 ]R .J .O .D a v i e s ,Z .C .T r a i l l ,a n dF .V .G l e e s o n ,“ R a n d o m i s e d
controlled trial of intrapleural streptokinase in community
acquiredpleuralinfection,”Thorax,vol.52,no.5,pp.461–421,
1997.
[42] I. M. Balfour-Lynn, E. Abrahamson, G. Cohen et al., “BTS
guidelines for the management of pleural infection in chil-
dren,” Thorax, vol. 60, no. 1, pp. i1–i21, 2005.10 Pulmonary Medicine
[43] J. E. Heﬀner, “Multicenter trials of treatment for empyema—
afteralltheseyears,”NewEnglandJournalofMedicine,vol.352,
no. 9, pp. 926–928, 2005.
[44] A. H. Diacon, C. F. N. Koegelenberg, C. T. Bolliger et al., “A
trial of intrapleural streptokinase,” New England Journal of
Medicine, vol. 352, no. 21, pp. 2243–2245, 2005.
[45] D. Bouros, K. M. Antoniou, and R. W. Light, “Intrapleural
streptokinase for pleural infection,” British Medical Journal,
vol. 332, no. 7534, pp. 133–134, 2006.
[46] C. A. Walker, M. B. Shirk, M. M. Tschampel, J. A. Visconti, B.
R. Morand, and C. Gu´ evremont, “Intrapleural alteplase in a
patient with complicated pleural eﬀusion,” Annals of Pharma-
cotherapy, vol. 37, no. 3, pp. 376–379, 2003.
[47] D. A. Skeete, E. J. Rutherford, S. A. Schlidt, J. E. Abrams, L. A.
Parker,andP.B.Rich,“Intrapleuraltissueplasminogenactiva-
tor for complicated pleural eﬀusions,” Journal of Trauma, vol.
57, no. 6, pp. 1178–1183, 2004.
[48] Y. Tokuda, D. Matsushima, G. H. Stein, and S. Miyagi,
“Intrapleural ﬁbrinolytic agents for empyema and compli-
cated parapneumonic eﬀusions: a meta-analysis,” Chest, vol.
129, no. 3, pp. 783–790, 2006.
[49] R. Cameron and H. R. Davies, “Intra-pleural ﬁbrinolytic ther-
apy versus conservative management in the treatment of adult
parapneumonic eﬀusions and empyema,” Cochrane Database
of Systematic Reviews, no. 2, article CD002312, 2008.
[50] G. Simpson, D. Roomes, and M. Heron, “Eﬀects of streptok-
inase and deoxyribonuclease on viscosity of human surgical
and empyema pus,” Chest, vol. 117, no. 6, pp. 1728–1733,
2000.
[51] N. M. Rahman, N. A. Maskell, A. West et al., “Intrapleural use
of tissue plasminogen activator and DNase in pleural infec-
tion,” New England Journal of Medicine, vol. 365, no. 6, pp.
518–526, 2011.
[52] J. R. Roberts, D. S. Weiman, D. L. Miller, A. Y. Aﬁﬁ, and R.
R. Kraeger, “Minimally invasive surgery in the treatment of
empyema: intraoperative decision making,” Annals of Thoracic
Surgery, vol. 76, no. 1, pp. 225–230, 2003.
[53] J. M. Tschopp, C. Boutin, P. Astoul et al., “Talcage by medical
thoracoscopyforprimaryspontaneouspneumothoraxismore
cost-eﬀective than drainage: a randomised study,” European
Respiratory Journal, vol. 20, no. 4, pp. 1003–1009, 2002.
[54] J. M. Tschopp, M. Brutsche, and J. G. Frey, “Treatment of
complicated spontaneous pneumothorax by simple talc pleu-
rodesis under thoracoscopy and local anaesthesia,” Thorax,
vol. 52, no. 4, pp. 329–332, 1997.
[55] R.Loddenkemper,“Thoracoscopy—stateoftheart,”European
Respiratory Journal, vol. 11, no. 1, pp. 213–221, 1998.
[56] M. H. Brutsche, G. F. Tassi, S. Gy¨ orik et al., “Treatment of
sonographically stratiﬁed multiloculated thoracic empyema
by medical thoracoscopy,” Chest, vol. 128, no. 5, pp. 3303–
3309, 2005.
[ 5 7 ]G .F .T a s s i ,R .J .O .D a v i e s ,a n dM .N o p p e n ,“ A d v a n c e dt e c h -
niques in medical thoracoscopy,” European Respiratory Jour-
nal, vol. 28, no. 5, pp. 1051–1059, 2006.
[58] A. J. Drain, J. I. Ferguson, R. Sayeed, S. Wilkinson, and A.
Ritchie, “Deﬁnitive management of advanced empyema by
two-windowvideo-assistedsurgery,”AsianCardiovascularand
Thoracic Annals, vol. 15, no. 3, pp. 238–239, 2007.
[59] D. A. Waller, “Thoracoscopy in management of postpneu-
monic pleural infections,” Current Opinion in Pulmonary
Medicine, vol. 8, no. 4, pp. 323–326, 2002.
[60] P. C. Cassina, M. Hauser, L. Hillejan, D. Greschuchna, G.
Stamatis, and J. Deslauriers, “Video-assisted thoracoscopy in
the treatment of pleural empyema: stage-based management
and outcome,” Journal of Thoracic and Cardiovascular Surgery,
vol. 117, no. 2, pp. 234–238, 1999.
[61] S.A.Sasse,“Parapneumoniceﬀusionsandempyema,” Current
Opinion in Pulmonary Medicine, vol. 2, no. 4, pp. 320–326,
1996.
[62] R. J. Thurer, “Decortication in thoracic empyema: indications
and surgical technique,” Chest Surgery Clinics of North Amer-
ica, vol. 6, no. 3, pp. 461–490, 1996.
[63] A.K.Mandal,H.Thadepalli,A.K.Mandal,andU.Chettipally,
“Outcome of primary empyema thoracis: therapeutic and
microbiologic aspects,” Annals of Thoracic Surgery, vol. 66, no.
5, pp. 1782–1786, 1998.
[64] V. Pothula and D. J. Krellenstein, “Early aggressive surgical
management of parapneumonic empyemas,” Chest, vol. 105,
no. 3, pp. 832–836, 1994.
[65] T. A. A. Mackinlay, G. A. Lyons, D. J. Chimondeguy, M. A.
Barboza Piedras, G. Angaramo, and J. Emery, “VATS debride-
ment versus thoracotomy in the treatment of loculated
postpneumoniaempyema,”AnnalsofThoracicSurgery,vol.61,
no. 6, pp. 1626–1630, 1996.